2.4.0.6 Html 112 196 1 false 30 0 false 7 false false R1.htm 101 - Document - Document and Entity Information Sheet http://www.galectintherapeutics.com/taxonomy/role/DocumentDocumentandEntityInformation Document and Entity Information true false R2.htm 103 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassified Condensed Consolidated Balance Sheets false false R3.htm 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical Condensed Consolidated Balance Sheets (Parenthetical) false false R4.htm 105 - Statement - Condensed Consolidated Statements Of Operations Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfIncomeAlternative Condensed Consolidated Statements Of Operations false false R5.htm 106 - Statement - Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) false false R6.htm 107 - Statement - Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical) false false R7.htm 108 - Statement - Condensed Consolidated Statements Of Cash Flows Sheet http://www.galectintherapeutics.com/taxonomy/role/StatementOfCashFlowsIndirect Condensed Consolidated Statements Of Cash Flows false false R8.htm 109 - Disclosure - Basis of Presentation Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsBasisOfAccounting Basis of Presentation false false R9.htm 110 - Disclosure - Agreement with PROCAPS S.A. Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock Agreement with PROCAPS S.A. false false R10.htm 111 - Disclosure - Accrued Expenses Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Accrued Expenses false false R11.htm 112 - Disclosure - Stock-Based Compensation Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Stock-Based Compensation false false R12.htm 113 - Disclosure - Common Stock Warrants Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock Common Stock Warrants false false R13.htm 114 - Disclosure - Common Stock and Warrant Offering and Reverse Split Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockWarrantsTextBlock Common Stock and Warrant Offering and Reverse Split false false R14.htm 115 - Disclosure - Fair Value of Financial Instruments Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock Fair Value of Financial Instruments false false R15.htm 116 - Disclosure - Loss Per Share Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock Loss Per Share false false R16.htm 117 - Disclosure - Commitments, Contingencies and Legal Proceedings Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock Commitments, Contingencies and Legal Proceedings false false R17.htm 118 - Disclosure - Accrued Expenses (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsAccountsPayableAndAccruedLiabilitiesDisclosureTextBlockTables Accrued Expenses (Tables) false false R18.htm 119 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables Stock-Based Compensation (Tables) false false R19.htm 120 - Disclosure - Common Stock Warrants (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables Common Stock Warrants (Tables) false false R20.htm 121 - Disclosure - Loss Per Share (Tables) Sheet http://www.galectintherapeutics.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables Loss Per Share (Tables) false false R21.htm 122 - Disclosure - Basis of Presentation - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureBasisOfPresentationAdditionalInformation Basis of Presentation - Additional Information (Detail) false false R22.htm 123 - Disclosure - Agreement with Procaps S.a. - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureAgreementWithProcapsSaAdditionalInformation Agreement with Procaps S.a. - Additional Information (Detail) false false R23.htm 124 - Disclosure - Accrued Expenses (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureAccruedExpenses Accrued Expenses (Detail) false false R24.htm 125 - Disclosure - Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationExpenseRelatedToCommonStockOptionsCommonStockRestrictedCommonStockAndCommonStockWarrants Stock-Based Compensation Expense Related to Common Stock Options, Common Stock, Restricted Common Stock and Common Stock Warrants (Detail) false false R25.htm 126 - Disclosure - Summary of Stock Option Activity (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureSummaryOfStockOptionActivity Summary of Stock Option Activity (Detail) false false R26.htm 127 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation Stock-Based Compensation - Additional Information (Detail) false false R27.htm 128 - Disclosure - Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureWeightedAverageAssumptionsUsedToDetermineFairValueOfOptionsGranted Weighted Average Assumptions Used to Determine Fair Value of Options Granted (Detail) false false R28.htm 129 - Disclosure - Summary of Stock Warrant Activity (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureSummaryOfStockWarrantActivity Summary of Stock Warrant Activity (Detail) false false R29.htm 130 - Disclosure - Common Stock Warrants - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommonStockWarrantsAdditionalInformation Common Stock Warrants - Additional Information (Detail) false false R30.htm 131 - Disclosure - Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommonStockAndWarrantOfferingAndReverseSplitAdditionalInformation Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail) false false R31.htm 132 - Disclosure - Computation Of Diluted Net Loss Per Share (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureComputationOfDilutedNetLossPerShare Computation Of Diluted Net Loss Per Share (Detail) false false R32.htm 133 - Disclosure - Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureDilutiveSharesWhichCouldExistPursuantToExerciseOfOutstandingStockInstrumentsAndWhichWereNotIncludedInCalculation Dilutive Shares Which Could Exist Pursuant to Exercise of Outstanding Stock Instruments and Which were not Included in Calculation (Detail) false false R33.htm 134 - Disclosure - Commitments, Contingencies and Legal Proceedings - Additional Information (Detail) Sheet http://www.galectintherapeutics.com/taxonomy/role/DisclosureCommitmentsContingenciesAndLegalProceedingsAdditionalInformation Commitments, Contingencies and Legal Proceedings - Additional Information (Detail) false false All Reports Book All Reports Element us-gaap_EmployeeRelatedLiabilitiesCurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromIssuanceOrSaleOfEquity had a mix of decimals attribute values: -3 0. Element us-gaap_ShareBasedCompensation had a mix of decimals attribute values: -3 0. Element us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate had a mix of decimals attribute values: 3 4 5. 'Monetary' elements on report '108 - Statement - Condensed Consolidated Statements Of Cash Flows' had a mix of different decimal attribute values. 'Monetary' elements on report '122 - Disclosure - Basis of Presentation - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '123 - Disclosure - Agreement with Procaps S.a. - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '131 - Disclosure - Common Stock and Warrant Offering and Reverse Split - Additional Information (Detail)' had a mix of different decimal attribute values. 'Monetary' elements on report '134 - Disclosure - Commitments, Contingencies and Legal Proceedings - Additional Information (Detail)' had a mix of different decimal attribute values. Process Flow-Through: 103 - Statement - Condensed Consolidated Balance Sheets Process Flow-Through: Removing column 'Sep. 30, 2011' Process Flow-Through: Removing column 'Dec. 31, 2010' Process Flow-Through: 104 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Process Flow-Through: Removing column 'Mar. 22, 2012' Process Flow-Through: 105 - Statement - Condensed Consolidated Statements Of Operations Process Flow-Through: 107 - Statement - Consolidated Statement Of Changes In Redeemable Convertible Preferred Stock And Stockholders' Equity (Deficit) (Parenthetical) Process Flow-Through: 108 - Statement - Condensed Consolidated Statements Of Cash Flows galt-20120930.xml galt-20120930.xsd galt-20120930_cal.xml galt-20120930_def.xml galt-20120930_lab.xml galt-20120930_pre.xml true true